EGFR+ Lung Cancer

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer

Nuances in Treating Squamous Cell Lung Cancer

Leena Gandhi, MD, PhD, discusses&nbsp;the ongoing phase III ALEX study, which is exploring alectinib as a first-line treatment option for&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer.

Julie R. Brahmer, MD, discusses&nbsp;5-year follow-up data from the CA209-003 study of nivolumab for patients with metastatic non&ndash;small cell lung cancer.

Sukhmani Padda, MD, discusses&nbsp;the status of ongoing trials participating in the race to the frontline in lung cancer.

According to findings from the phase III ALEX trial, alectinib reduced the risk of disease progression or death compared with crizotinib as a frontline treatment for patients with <em>ALK</em>-positive non&ndash;small cell lung cancer.&nbsp;

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.

According to 5-year follow-up data&nbsp;from the CA209-003 study, long-term survival in patients with metastatic non&ndash;small cell lung cancer (NSCLC) who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of patients surviving after 5 years.

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses an ongoing trial at Yale Cancer Center exploring the use of positive messaging in smoking cessation counseling for lung cancer during the AACR Annual Meeting.

The European Union has approved the combination of dabrafenib and trametinib for patients with <em>BRAF</em> V600-positive advanced or metastatic non-small cell lung cancer.&nbsp;

Osimertinib (Tagrisso) has been granted a full approval as a treatment for patients with metastatic EGFR T790M mutation-positive non&ndash;small cell lung cancer following prior treatment with an EGFR TKI.

Preliminary results from an ongoing phase I study have revealed the potential of a novel small-molecule inhibitor in 3 combinations for patients with advanced cancers.

Thomas J. Lynch Jr, MD, has been appointed the executive vice president and chief scientific officer for Bristol-Myers Squibb, effective March 16, 2017. He will succeed Francis Cuss, MB BChir, who will be retiring from the company. Lynch will simultaneously step down from the Board of Directors at Bristol-Myers Squibb, effective March 15, 2017.

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women&rsquo;s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.

This manuscript focuses on the latest clinical developments of newer generation selective CDK inhibitors in lung cancer.

Alectinib has been approved by the European Commission as a treatment for patients with metastatic ALK-positive non&ndash;small cell lung cancer following progression on crizotinib.

Ceritinib has been granted a priority review by the FDA as a first-line treatment for patients with <em>ALK</em>-positive, metastatic NSCLC.